Oncoceutics: Philadelphia biopharma firm shakes up its leadership

Philadelphia biopharmaceutical firm Oncoceutics Inc. said Wednesday its CEO and co-founder Wolfgang Oster has left the company as part of a leadership change. His departure, which also included stepping down from the company's board of directors, was effective April 3. Oncoceutics is a clinical-stage biopharma firm developing a novel class of compounds called imipridones for cancer treatment. Dr. Lee Schalop, one of the company's co-founders and previously the company's chief operating officer,...